ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 935,10
-0,62%
Dow Jones
37 903,29
0,00%
DAX
17 951,52
0,16%
Brent Oil
84,075
0,64%
Bitcoin
58 672,70
0,75%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Redhill Biopharma Ltd (RDHL)

  7. Redhill Biopharma Ltd (RDHL) Actualités

RDHL Redhill Biopharma Ltd

0,4507
-0,0003 (-0,07%)
Avant marché
Dernière mise à jour : 14:04:54
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Redhill Biopharma Ltd RDHL NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,0003 -0,07% 0,4507 14:04:54
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,451
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
24/4/202413:00PRNUSRedHill Announces First Patient Enrolled in U.S...
08/4/202415:23PRNUSRedHill Biopharma Announces Full-Year 2023 Results and..
02/4/202413:00PRNUSRedHill Biopharma Announces $1.25 Million Registered Direct..
11/3/202412:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/3/202412:00PRNUSRedHill Announces New USPTO Patent Covering Talicia® Through..
05/3/202413:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/3/202413:00PRNUSRedHill's Opaganib Selected for Evaluation by BARDA and NIH..
20/2/202422:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/2/202413:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/2/202413:00PRNUSRedHill's Opaganib Protects Against Radiation-Induced Lung..
16/2/202414:54EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
16/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
13/2/202422:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/2/202422:10EDGAR2Form SC 13G - Statement of acquisition of beneficial..
01/2/202416:22EDGAR2Form SC 13G - Statement of acquisition of beneficial..
26/1/202418:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/1/202418:46PRNUSRedHill Biopharma Announces Closing of $8 Million Registered..
26/1/202415:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/1/202415:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
25/1/202415:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/1/202415:05PRNUSRedHill Biopharma Announces $8 Million Registered Direct..
25/1/202412:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/1/202412:00PRNUSRedHill Announces New USPTO Patent Grant for Talicia® for H...
20/12/202314:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202314:45PRNUSRedHill and U.S. Army Announce Opaganib and RHB-107..
12/12/202313:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/12/202313:00PRNUSRedHill Biopharma Regains Compliance with Nasdaq Minimum Bid..
06/12/202313:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202313:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202313:00PRNUSRedHill Announces New, Non-Dilutive External Funding of..
01/12/202322:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/11/202313:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/11/202313:00PRNUSRedHill Biopharma Announces FDA Grant of 5-Year U.S. Market..
16/11/202318:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/11/202314:00PRNUSRedHill Biopharma Announces the Transfer of its Listing to..
26/10/202322:52EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
23/10/202322:06EDGAR2Form F-3/A - Registration statement by foreign private..
16/10/202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/10/202314:13EDGAR2Form F-3 - Registration statement by foreign private issuers
10/10/202315:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/10/202313:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/10/202313:00PRNUSRedHill and U.S. Army Announce Opaganib's Ebola Virus..
29/9/202314:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/9/202322:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/9/202322:15PRNUSRedHill Biopharma Announces Receipt of Nasdaq Notification..
18/9/202313:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/9/202313:00PRNUSRedHill Announces FDA sNDA Approval for Talicia®
05/9/202313:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202313:00PRNUSRedHill Announces New USPTO Notice of Patent Allowance for..
17/8/202313:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

Dernières Valeurs Consultées

NASDAQ
RDHL
Redhill Biopharma
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés